Capillary infantile hemangioma

Summary

Capillary infantile hemangioma (MONDO:0011191) is a disease caused by FLT4 (GenCC Strong), with 6 cohort genes and 1 clinical trial.

At a glance

• Causal gene: FLT4 (GenCC Strong)
• Cohort genes: 6
• ClinVar variants: 30
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	capillary infantile hemangioma
Mondo ID	MONDO:0011191
MeSH	C535860
OMIM	602089
Orphanet	464293, 91415
NCIT	C6645
UMLS	C1865871
MedGen	355573
Is cancer (heuristic)	no

Also known as: HCI · hemangioma, capillary infantile · hemangioma, capillary infantile, somatic · hemangioma, hereditary capillary · hereditary capillary infantile hemangioma

Data availability: 30 ClinVar variants · 2 GenCC gene-disease records.

Disease family

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › cardiovascular organ benign neoplasm › benign blood vessel neoplasm › hemangioma › capillary hemangioma › capillary infantile hemangioma

Related subtypes (5): cherry hemangioma, breast capillary hemangioma, hemangioblastoma, eyelid capillary hemangioma, pyogenic granuloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

30 retrieved; paginated sample, class counts are floors:

19 uncertain significance, 3 benign, 2 pathogenic, 2 likely benign, 1 benign/likely benign, 1 risk factor, 1 conflicting classifications of pathogenicity, 1 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
1691335	NM_002890.3(RASA1):c.1657dup (p.Tyr553fs)	CCNH	Pathogenic	criteria provided, single submitter
12317	NM_002253.4(KDR):c.3439C>T (p.Pro1147Ser)	KDR	Pathogenic	no assertion criteria provided
932061	NM_182925.5(FLT4):c.3410C>T (p.Pro1137Leu)	FLT4	Likely pathogenic	criteria provided, multiple submitters, no conflicts
4390	NM_032208.3(ANTXR1):c.976G>A (p.Ala326Thr)	ANTXR1	risk factor	no assertion criteria provided
445474	NM_032208.3(ANTXR1):c.1553C>T (p.Ala518Val)	ANTXR1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1691351	NM_001291303.3(FAT4):c.9273C>A (p.Phe3091Leu)	FAT4	Uncertain significance	criteria provided, multiple submitters, no conflicts
1691352	NM_001291303.3(FAT4):c.13985C>G (p.Ala4662Gly)	FAT4	Uncertain significance	criteria provided, single submitter
2501818	NM_182925.5(FLT4):c.3179G>A (p.Arg1060Gln)	FLT4	Uncertain significance	criteria provided, multiple submitters, no conflicts
3279267	NM_182925.5(FLT4):c.3778A>C (p.Met1260Leu)	FLT4	Uncertain significance	criteria provided, multiple submitters, no conflicts
3592190	NM_182925.5(FLT4):c.3712G>A (p.Gly1238Arg)	FLT4	Uncertain significance	criteria provided, single submitter
3592191	NM_182925.5(FLT4):c.1109A>G (p.Lys370Arg)	FLT4	Uncertain significance	criteria provided, single submitter
3892328	NM_182925.5(FLT4):c.200C>T (p.Ala67Val)	FLT4	Uncertain significance	criteria provided, single submitter
1710210	NM_002253.4(KDR):c.3006G>C (p.Leu1002Phe)	KDR	Uncertain significance	criteria provided, single submitter
2348108	NM_002253.4(KDR):c.2270C>G (p.Ala757Gly)	KDR	Uncertain significance	criteria provided, multiple submitters, no conflicts
2672213	NM_002253.4(KDR):c.1136C>T (p.Ala379Val)	KDR	Uncertain significance	criteria provided, multiple submitters, no conflicts
2672215	NM_002253.4(KDR):c.3663T>C (p.Ser1221=)	KDR	Uncertain significance	criteria provided, single submitter
3113923	NM_002253.4(KDR):c.1247T>C (p.Val416Ala)	KDR	Uncertain significance	criteria provided, multiple submitters, no conflicts
3237450	NM_002253.4(KDR):c.1616G>A (p.Gly539Glu)	KDR	Uncertain significance	criteria provided, single submitter
3891470	NM_002253.4(KDR):c.1259C>T (p.Pro420Leu)	KDR	Uncertain significance	criteria provided, single submitter
3891471	NM_002253.4(KDR):c.1567A>C (p.Asn523His)	KDR	Uncertain significance	criteria provided, single submitter
3891472	NM_002253.4(KDR):c.2381G>A (p.Gly794Glu)	KDR	Uncertain significance	criteria provided, single submitter
3891473	NM_002253.4(KDR):c.3193G>A (p.Ala1065Thr)	KDR	Uncertain significance	criteria provided, single submitter
3891475	NM_002253.4(KDR):c.953A>T (p.Asn318Ile)	KDR	Uncertain significance	criteria provided, single submitter
545478	NM_002473.6(MYH9):c.5308C>T (p.Arg1770Cys)	MYH9	Uncertain significance	criteria provided, single submitter
262019	NM_032208.3(ANTXR1):c.1185+16C>A	ANTXR1	Benign	criteria provided, multiple submitters, no conflicts
16264	NM_182925.5(FLT4):c.2860C>T (p.Pro954Ser)	FLT4	Benign/Likely benign	criteria provided, multiple submitters, no conflicts
12318	NM_002253.4(KDR):c.1444T>C (p.Cys482Arg)	KDR	Likely benign	criteria provided, multiple submitters, no conflicts
134619	NM_002253.4(KDR):c.1116G>C (p.Glu372Asp)	KDR	Benign	criteria provided, multiple submitters, no conflicts
518355	NM_002253.4(KDR):c.3848+15T>C	KDR	Benign	criteria provided, single submitter
623416	NM_002253.4(KDR):c.2312C>T (p.Thr771Met)	KDR	Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 26 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
FLT4	Strong	Autosomal dominant	capillary infantile hemangioma	10
ANTXR1	Limited	Autosomal dominant	capillary infantile hemangioma	16

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ANTXR1	Orphanet:2067	GAPO syndrome
FLT4	Orphanet:3303	Tetralogy of Fallot
FLT4	Orphanet:79452	Milroy disease
FAT4	Orphanet:2136	Hennekam syndrome
FAT4	Orphanet:314679	Cerebrofacioarticular syndrome
KDR	Orphanet:3303	Tetralogy of Fallot
MYH9	Orphanet:182050	MYH9-related syndromic thrombocytopenia
MYH9	Orphanet:477742	Nodular fasciitis
MYH9	Orphanet:90635	Rare autosomal dominant non-syndromic sensorineural deafness type DFNA

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	6

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ANTXR1	HGNC:21014	ENSG00000169604	Q9H6X2	Anthrax toxin receptor 1	gencc,clinvar
FLT4	HGNC:3767	ENSG00000037280	P35916	Vascular endothelial growth factor receptor 3	gencc,clinvar
CCNH	HGNC:1594	ENSG00000134480	P51946	Cyclin-H	clinvar
FAT4	HGNC:23109	ENSG00000196159	Q6V0I7	Protocadherin Fat 4	clinvar
KDR	HGNC:6307	ENSG00000128052	P35968	Vascular endothelial growth factor receptor 2	clinvar
MYH9	HGNC:7579	ENSG00000100345	P35579	Myosin-9	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ANTXR1	Anthrax toxin receptor 1	Plays a role in cell attachment and migration.
FLT4	Vascular endothelial growth factor receptor 3	Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic developm…
CCNH	Cyclin-H	Regulates CDK7, the catalytic subunit of the CDK-activating kinase (CAK) enzymatic complex.
FAT4	Protocadherin Fat 4	Cadherins are calcium-dependent cell adhesion proteins.
KDR	Vascular endothelial growth factor receptor 2	Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD.
MYH9	Myosin-9	Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.

Protein-family classification

Druggable: 2 · Difficult: 1 · Unknown: 3 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	2	9.2×	0.053
Scaffold/PPI	1	2.9×	0.451
Other/Unknown	3	0.9×	0.758

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ANTXR1	Other/Unknown	no		VWF_A, Anthrax_toxin_rcpt_C, Anthrax_toxin_rcpt_extracel
FLT4	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Tyr_kinase_rcpt_3_CS
CCNH	Other/Unknown	no		Cyclin_N, Cyclin-like_dom, CyclinH/Ccl1
FAT4	Other/Unknown	no		EGF-type_Asp/Asn_hydroxyl_site, EGF, Laminin_G
KDR	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Tyr_kinase_rcpt_3_CS
MYH9	Scaffold/PPI	no		IQ_motif_EF-hand-BS, Myosin_head_motor_dom-like, Myosin_tail

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	6
unknown	0

Top tissues across cohort

Tissue	Cohort genes
stromal cell of endometrium	2
calcaneal tendon	2
decidua	1
palpebral conjunctiva	1
left lobe of thyroid gland	1
right lobe of thyroid gland	1
thyroid gland	1
left testis	1
right testis	1
blood vessel layer	1
cortical plate	1
germinal epithelium of ovary	1
lower lobe of lung	1
parietal pleura	1
ascending aorta	1
thoracic aorta	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ANTXR1	270	ubiquitous	marker	stromal cell of endometrium, decidua, palpebral conjunctiva
FLT4	172	broad	marker	right lobe of thyroid gland, left lobe of thyroid gland, thyroid gland
CCNH	297	ubiquitous	marker	calcaneal tendon, left testis, right testis
FAT4	231	ubiquitous	marker	calcaneal tendon, cortical plate, blood vessel layer
KDR	267	broad	marker	germinal epithelium of ovary, lower lobe of lung, parietal pleura
MYH9	279	ubiquitous	marker	stromal cell of endometrium, ascending aorta, thoracic aorta

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MYH9	5,533
KDR	4,960
FLT4	2,411
CCNH	2,116
ANTXR1	2,039
FAT4	1,932

Intra-cohort edges

A	B	Sources
ANTXR1	KDR	string_interaction
ANTXR1	MYH9	intact
FLT4	KDR	intact, string_interaction

Structural data

PDB: 6 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
KDR	P35968	54
CCNH	P51946	47
MYH9	P35579	8
ANTXR1	Q9H6X2	5
FLT4	P35916	2
FAT4	Q6V0I7	2

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 108. Enrichment computed across 6 evidence-associated genes (5 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
VEGF binds to VEGFR leading to receptor dimerization	2	507.6×	6e-04	FLT4, KDR
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	2	64.3×	0.020	FLT4, KDR
Neuropilin interactions with VEGF and VEGFR	1	571.0×	0.043	KDR
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB	1	456.8×	0.043	KDR
CD163 mediating an anti-inflammatory response	1	228.4×	0.043	MYH9
Uptake and function of anthrax toxins	1	190.3×	0.043	ANTXR1
Sema4D in semaphorin signaling	1	134.3×	0.043	MYH9
RHO GTPases activate CIT	1	120.2×	0.043	MYH9
RHO GTPases Activate ROCKs	1	120.2×	0.043	MYH9
Sema4D induced cell migration and growth-cone collapse	1	114.2×	0.043	MYH9
VEGFR2 mediated cell proliferation	1	114.2×	0.043	KDR
NOTCH4 Intracellular Domain Regulates Transcription	1	114.2×	0.043	FLT4
RHO GTPases activate PAKs	1	108.8×	0.043	MYH9
Global Genome Nucleotide Excision Repair (GG-NER)	1	91.4×	0.043	CCNH
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	1	81.6×	0.043	CCNH
RNA Pol II CTD phosphorylation and interaction with CE	1	81.6×	0.043	CCNH
Semaphorin interactions	1	78.8×	0.043	MYH9
G1 Phase	1	78.8×	0.043	CCNH
Anti-inflammatory response favouring Leishmania parasite infection	1	78.8×	0.043	MYH9
Leishmania parasite growth and survival	1	78.8×	0.043	MYH9
EPHA-mediated growth cone collapse	1	76.1×	0.043	MYH9
mRNA Capping	1	76.1×	0.043	CCNH
Parasite infection	1	69.2×	0.043	MYH9
Leishmania phagocytosis	1	69.2×	0.043	MYH9
Formation of the Early Elongation Complex	1	67.2×	0.043	CCNH
Formation of the HIV-1 Early Elongation Complex	1	67.2×	0.043	CCNH
HIV Transcription Elongation	1	67.2×	0.043	CCNH
RNA Polymerase I Transcription Termination	1	65.3×	0.043	CCNH
RHO GTPases activate PKNs	1	63.4×	0.043	MYH9
Cyclin A/B1/B2 associated events during G2/M transition	1	61.7×	0.043	CCNH

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
lymph vessel development	2	624.1×	4e-04	FLT4, KDR
vascular endothelial growth factor signaling pathway	2	351.1×	7e-04	FLT4, KDR
cellular response to vascular endothelial growth factor stimulus	2	187.2×	0.002	FLT4, KDR
vascular endothelial growth factor receptor signaling pathway	2	160.5×	0.002	FLT4, KDR
peptidyl-tyrosine phosphorylation	2	140.4×	0.002	FLT4, KDR
lung alveolus development	2	117.0×	0.002	FLT4, KDR
positive regulation of protein phosphorylation	2	92.1×	0.003	FLT4, KDR
positive regulation of endothelial cell migration	2	83.8×	0.003	FLT4, KDR
positive regulation of endothelial cell proliferation	2	77.0×	0.003	FLT4, KDR
positive regulation of nitric oxide-cGMP mediated signal transduction	1	2808.7×	0.004	KDR
cell surface receptor protein tyrosine kinase signaling pathway	2	57.9×	0.005	FLT4, KDR
uropod organization	1	1404.3×	0.005	MYH9
cortical granule exocytosis	1	1404.3×	0.005	MYH9
negative regulation of actin filament severing	1	1404.3×	0.005	MYH9
positive regulation of protein processing in phagocytic vesicle	1	1404.3×	0.005	MYH9
protein autophosphorylation	2	48.4×	0.005	FLT4, KDR
cytokinetic process	1	936.2×	0.006	MYH9
regulation of blood vessel remodeling	1	936.2×	0.006	FLT4
cellular response to hydrogen sulfide	1	936.2×	0.006	KDR
regulation of plasma membrane repair	1	936.2×	0.006	MYH9
regulation of cell shape	2	41.0×	0.006	KDR, MYH9
post-embryonic camera-type eye morphogenesis	1	702.2×	0.007	KDR
establishment of meiotic spindle localization	1	702.2×	0.007	MYH9
negative regulation of extracellular matrix assembly	1	702.2×	0.007	ANTXR1
endocardium development	1	561.7×	0.007	KDR
cytoplasmic actin-based contraction involved in cell motility	1	561.7×	0.007	MYH9
blood vessel endothelial cell differentiation	1	561.7×	0.007	KDR
regulation of hematopoietic progenitor cell differentiation	1	561.7×	0.007	KDR
regulation of bone development	1	561.7×	0.007	KDR
positive regulation of ERK1 and ERK2 cascade	2	28.4×	0.008	FLT4, KDR

Therapeutics

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 4 · Undrugged: 2

Druggability breadth: 4 of 6 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
FLT4	FEDRATINIB
CCNH	ABEMACICLIB
KDR	VANDETANIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
KDR	172	4
FLT4	72	4
CCNH	28	4
MYH9	1	2
ANTXR1	0	0
FAT4	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
FEDRATINIB	4	FLT4, KDR
TIVOZANIB	4	FLT4, KDR
LENVATINIB	4	FLT4, KDR
AXITINIB	4	FLT4, KDR
SORAFENIB	4	FLT4, KDR
INFIGRATINIB PHOSPHATE	4	FLT4, KDR
INFIGRATINIB	4	FLT4, KDR
REGORAFENIB	4	FLT4, KDR
ENTRECTINIB	4	FLT4, KDR
CABOZANTINIB	4	FLT4, KDR
VANDETANIB	4	FLT4, KDR
NINTEDANIB ESYLATE	4	FLT4, KDR
FILGOTINIB	4	FLT4
BRIGATINIB	4	FLT4, KDR
FRUQUINTINIB	4	FLT4, KDR
PAZOPANIB	4	FLT4, KDR
NINTEDANIB	4	FLT4, KDR
SUNITINIB	4	FLT4, KDR
ERLOTINIB	4	FLT4, KDR
QUIZARTINIB	4	CCNH, FLT4, KDR
MIDOSTAURIN	4	FLT4, KDR
GEFITINIB	4	FLT4, KDR
ABEMACICLIB	4	CCNH, KDR
ADAGRASIB	4	CCNH
INDIGOTINDISULFONATE	4	KDR
PONATINIB	4	KDR
SORAFENIB TOSYLATE	4	KDR
PHENYL AMINOSALICYLATE	4	KDR
VEMURAFENIB	4	KDR
PIPERAZINE	4	KDR

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
KDR	2,687	Binding:2594, Functional:64, ADMET:27, Toxicity:2
FLT4	717	Binding:683, Functional:32, ADMET:2
CCNH	348	Binding:346, Functional:2
MYH9	10	Binding:10

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
FLT4	2.7.10.1	receptor protein-tyrosine kinase
KDR	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
FLT4	717
CCNH	348
KDR	2,687

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
FEDRATINIB	4	FLT4, KDR
TIVOZANIB	4	FLT4, KDR
LENVATINIB	4	FLT4, KDR
AXITINIB	4	FLT4, KDR
SORAFENIB	4	FLT4, KDR
INFIGRATINIB PHOSPHATE	4	FLT4, KDR
INFIGRATINIB	4	FLT4, KDR
REGORAFENIB	4	FLT4, KDR
ENTRECTINIB	4	FLT4, KDR
CABOZANTINIB	4	FLT4, KDR
VANDETANIB	4	FLT4, KDR
NINTEDANIB ESYLATE	4	FLT4, KDR
FILGOTINIB	4	FLT4
BRIGATINIB	4	FLT4, KDR
FRUQUINTINIB	4	FLT4, KDR
PAZOPANIB	4	FLT4, KDR
NINTEDANIB	4	FLT4, KDR
SUNITINIB	4	FLT4, KDR
ERLOTINIB	4	FLT4, KDR
QUIZARTINIB	4	CCNH, FLT4, KDR
MIDOSTAURIN	4	FLT4, KDR
GEFITINIB	4	FLT4, KDR
ABEMACICLIB	4	CCNH, KDR
ADAGRASIB	4	CCNH
INDIGOTINDISULFONATE	4	KDR
PONATINIB	4	KDR
SORAFENIB TOSYLATE	4	KDR
PHENYL AMINOSALICYLATE	4	KDR
VEMURAFENIB	4	KDR
PIPERAZINE	4	KDR

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	FLT4, CCNH, KDR
B	Phased (≥1) drug, not yet approved	1	MYH9
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	ANTXR1, FAT4

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
ANTXR1	0	KDR
FAT4	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03173352	Not specified	UNKNOWN	A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China